Sartorius Stedim Biotech S.A. (EPA: DIM)
France
· Delayed Price · Currency is EUR 175.00
+6.40 (3.80%)
Nov 22, 2024, 5:35 PM CET
Sartorius Stedim Biotech Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 2,736 | 2,776 | 3,493 | 2,887 | 1,910 | 1,441 | Upgrade
|
| Revenue Growth (YoY) | -7.54% | -20.53% | 20.98% | 51.15% | 32.59% | 18.84% | Upgrade
|
| Cost of Revenue | 1,550 | 1,542 | 1,675 | 1,334 | 906.76 | 692.28 | Upgrade
|
| Gross Profit | 1,185 | 1,234 | 1,817 | 1,553 | 1,003 | 748.29 | Upgrade
|
| Selling, General & Admin | 641.2 | 617.8 | 612.3 | 531.9 | 391.85 | 317.63 | Upgrade
|
| Research & Development | 143 | 129.5 | 132.4 | 110.5 | 84.45 | 79.22 | Upgrade
|
| Other Operating Expenses | 2.3 | 17.5 | 18.2 | -9.6 | 23.89 | 3.54 | Upgrade
|
| Operating Expenses | 786.5 | 764.8 | 762.9 | 632.8 | 500.19 | 400.39 | Upgrade
|
| Operating Income | 398.9 | 468.7 | 1,054 | 920.2 | 503.14 | 347.9 | Upgrade
|
| Interest Expense | -216.1 | -115.4 | -18.2 | -10.2 | -6.51 | -3.86 | Upgrade
|
| Interest & Investment Income | - | 6.2 | 0.5 | 0.3 | 0.51 | 0.34 | Upgrade
|
| Currency Exchange Gain (Loss) | -18.6 | -18.6 | -32.8 | 12.3 | -14.66 | -11.68 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.8 | 0.6 | -4.6 | -37.1 | 1.08 | 1.54 | Upgrade
|
| EBT Excluding Unusual Items | 165 | 341.5 | 999.3 | 885.5 | 483.55 | 334.23 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -20.3 | -4.3 | -0.3 | Upgrade
|
| Other Unusual Items | 59.6 | 59.6 | 131.1 | -218.5 | -18.56 | -16.51 | Upgrade
|
| Pretax Income | 224.6 | 401.1 | 1,130 | 646.7 | 460.69 | 317.42 | Upgrade
|
| Income Tax Expense | 59.9 | 89 | 250.5 | 232.4 | 122.1 | 81.38 | Upgrade
|
| Earnings From Continuing Operations | 164.7 | 312.1 | 879.9 | 414.3 | 338.6 | 236.04 | Upgrade
|
| Minority Interest in Earnings | -4.1 | -2.4 | -3.8 | 0.1 | -2.67 | -1.54 | Upgrade
|
| Net Income | 160.6 | 309.7 | 876.1 | 414.4 | 335.93 | 234.5 | Upgrade
|
| Net Income to Common | 160.6 | 309.7 | 876.1 | 414.4 | 335.93 | 234.5 | Upgrade
|
| Net Income Growth | -65.12% | -64.65% | 111.41% | 23.36% | 43.25% | 12.71% | Upgrade
|
| Shares Outstanding (Basic) | 95 | 92 | 92 | 92 | 92 | 92 | Upgrade
|
| Shares Outstanding (Diluted) | 95 | 92 | 92 | 92 | 92 | 92 | Upgrade
|
| Shares Change (YoY) | 3.60% | -0.00% | -0.01% | -0.00% | 0.00% | 0.00% | Upgrade
|
| EPS (Basic) | 1.68 | 3.36 | 9.51 | 4.50 | 3.64 | 2.54 | Upgrade
|
| EPS (Diluted) | 1.68 | 3.36 | 9.51 | 4.50 | 3.64 | 2.54 | Upgrade
|
| EPS Growth | -66.34% | -64.65% | 111.45% | 23.51% | 43.31% | 12.53% | Upgrade
|
| Free Cash Flow | 503.7 | 272.8 | 181.7 | 377.9 | 257.69 | 174.16 | Upgrade
|
| Free Cash Flow Per Share | 5.28 | 2.96 | 1.97 | 4.10 | 2.80 | 1.89 | Upgrade
|
| Dividend Per Share | - | 0.690 | 1.440 | 1.260 | 0.680 | 0.340 | Upgrade
|
| Dividend Growth | - | -52.08% | 14.29% | 85.29% | 100.00% | -40.35% | Upgrade
|
| Gross Margin | 43.33% | 44.44% | 52.03% | 53.79% | 52.53% | 51.94% | Upgrade
|
| Operating Margin | 14.58% | 16.89% | 30.19% | 31.87% | 26.34% | 24.15% | Upgrade
|
| Profit Margin | 5.87% | 11.16% | 25.08% | 14.35% | 17.59% | 16.28% | Upgrade
|
| Free Cash Flow Margin | 18.41% | 9.83% | 5.20% | 13.09% | 13.49% | 12.09% | Upgrade
|
| EBITDA | 645.7 | 657.8 | 1,197 | 1,031 | 577.32 | 401.54 | Upgrade
|
| EBITDA Margin | 23.60% | 23.70% | 34.27% | 35.73% | 30.22% | 27.87% | Upgrade
|
| D&A For EBITDA | 246.8 | 189.1 | 142.5 | 111.2 | 74.18 | 53.64 | Upgrade
|
| EBIT | 398.9 | 468.7 | 1,054 | 920.2 | 503.14 | 347.9 | Upgrade
|
| EBIT Margin | 14.58% | 16.89% | 30.19% | 31.87% | 26.34% | 24.15% | Upgrade
|
| Effective Tax Rate | 26.67% | 22.19% | 22.16% | 35.94% | 26.50% | 25.64% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.